Haleon poised to deliver solid margin growth despite weaker cold season

Impact · against what's priced in

Haleon faces conflicting signals as a profit margin beat is offset by misses in organic sales growth and management guidance. Genflow Biosciences receives a valuation boost from strengthened IP protection for its core SIRT6 gene variant.

GENF+0.60

No priced-in read yet

In context

Accelerated US patent examination for the SIRT6 gene variant strengthens intellectual property protection across the company's entire therapeutic pipeline.

Read from the article alone

• guidance▲17%
• earnings▲4%
• healthcare▲3%
• GENF
• HLN
• organic growth
• pharma